USP10 and neoplasm: These results indicate that the combination of cisplatin and USP10 inhibition by P22077 exhibits a more potent inhibition of tumor growth than either single agent treatment, and suggest a novel strategy of combining USP10 inhibition with cisplatin for treatment of NSCLC.